Animal models of neurodegenerative diseases.

The prevalence of neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD), increases with age, and the number of affected patients is expected to increase worldwide in the next decades. Accurately understanding the etiopathogenic mechanisms of these diseases is a crucial step for developing disease-modifying drugs able to preclude their emergence or at least slow their progression. Animal models contribute to increase the knowledge on the pathophysiology of neurodegenerative diseases. These models reproduce different aspects of a given disease, as well as the histopathological lesions and its main symptoms. The purpose of this review is to present the main animal models for AD, PD, and Huntington's disease.

• Publication year

  2013

• Venue

  Revista Brasileira de Psiquiatria

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1590/1516-4446-2013-1157PMID 24271230
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Mouse Models of Huntington's Disease.

  2015cited by this paper
• Can zebrafish be used as animal model to study Alzheimer's disease?

  2012cited by this paper
• AMP Kinase Activation Mitigates Dopaminergic Dysfunction and Mitochondrial Abnormalities in Drosophila Models of Parkinson's Disease

  2012cited by this paper
• Modeling Parkinson's disease in primates: The MPTP model.

  2012cited by this paper
• Drosophila as a model to study mitochondrial dysfunction in Parkinson's disease.

  2012cited by this paper
• Genomics and bioinformatics of Parkinson's disease.

  2012cited by this paper
• Animal models of Alzheimer disease.

  2012cited by this paper
• Inflammation and adaptive immunity in Parkinson's disease.

  2012cited by this paper
• Influence of species differences on the neuropathology of transgenic Huntington's disease animal models.

  2012cited by this paper
• Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease

  2011cited by this paper
• A guide to neurotoxic animal models of Parkinson's disease.

  2011cited by this paper
• Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications

  2011cited by this paper
• The Novel Hydroxylamine Derivative NG-094 Suppresses Polyglutamine Protein Toxicity in Caenorhabditis elegans*

  2011cited by this paper
• Alzheimer's disease.

  2011cited by this paper
• IFN-γ signaling, with the synergistic contribution of TNF-α, mediates cell specific microglial and astroglial activation in experimental models of Parkinson's disease

  2011cited by this paper
• The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.

  2011cited by this paper
• Learning and memory in Drosophila: behavior, genetics, and neural systems.

  2011cited by this paper
• Animal models in the drug discovery pipeline for Alzheimer's disease

  2011cited by this paper
• Amyloid-dependent and amyloid-independent stages of Alzheimer disease.

  2011cited by this paper
• A tale on animal models of Parkinson's disease

  2011cited by this paper
• Intranasal Administration of Neurotoxicants in Animals: Support for the Olfactory Vector Hypothesis of Parkinson’s Disease

  2011cited by this paper
• Phosphorylation of parkin by Parkinson disease-linked kinase PINK1 activates parkin E3 ligase function and NF-kappaB signaling.

  2010cited by this paper
• Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration.

  2010cited by this paper
• The worldwide societal costs of dementia: Estimates for 2009

  2010cited by this paper
• Missing pieces in the Parkinson's disease puzzle

  2010cited by this paper
• Geographic and Ethnic Variation in Parkinson Disease: A Population-Based Study of US Medicare Beneficiaries

  2010cited by this paper
• Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models.

  2010cited by this paper
• Alzheimer's disease.

  2010cited by this paper
• Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade.

  2010cited by this paper
• Modeling Parkinson's disease

  2009cited by this paper
• Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease.

  2009cited by this paper
• Classification and basic pathology of Alzheimer disease

  2009cited by this paper
• Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models.

  2009cited by this paper
• From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease.

  2009cited by this paper
• Full-Length Human Mutant Huntingtin with a Stable Polyglutamine Repeat Can Elicit Progressive and Selective Neuropathogenesis in BACHD Mice

  2008cited by this paper
• Accumulation of N-terminal mutant huntingtin in mouse and monkey models implicated as a pathogenic mechanism in Huntington's disease.

  2008cited by this paper
• Aβ inhibits the proteasome and enhances amyloid and tau accumulation

  2008cited by this paper
• The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery

  2008cited by this paper
• Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model

  2007cited by this paper
• The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes.

  2007cited by this paper
• A Decade of Tau Transgenic Animal Models and Beyond

  2007cited by this paper
• Huntington's disease

  2007cited by this paper
• Identification of Potential Therapeutic Drugs for Huntington's Disease using Caenorhabditis elegans

  2007cited by this paper
• Alzheimer disease models and human neuropathology: similarities and differences

  2007cited by this paper
• Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin

  2006cited by this paper
• C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease.

  2006cited by this paper
• Pathways by which Abeta facilitates tau pathology.

  2006cited by this paper
• Progressive neurodegeneration in C. elegans model of tauopathy.

  2005cited by this paper
• α-Synuclein expression in the substantia nigra of MPTP-lesioned non-human primates

  2005cited by this paper
• Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates.

  2005cited by this paper
• Regulation of NMDA receptor trafficking by amyloid-beta.

  2005cited by this paper
• Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.

  2005cited by this paper
• Identification of combinatorial drug regimens for treatment of Huntington's disease using Drosophila.

  2005cited by this paper
• Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease

  2005cited by this paper
• MPTP as a Mitochondrial Neurotoxic Model of Parkinson's Disease

  2004cited by this paper
• Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death

  2004cited by this paper
• Huntingtin-protein interactions and the pathogenesis of Huntington's disease.

  2004cited by this paper
• APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1.

  2004cited by this paper
• Age-Dependent Neurodegeneration and Alzheimer-Amyloid Plaque Formation in Transgenic Drosophila

  2004cited by this paper
• The role of oxidative stress, impaired glycolysis and mitochondrial respiratory redox failure in the cytotoxic effects of 6-hydroxydopamine in vitro.

  2004cited by this paper
• BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease.

  2004cited by this paper
• Dissecting the pathological effects of human Abeta40 and Abeta42 in Drosophila: a potential model for Alzheimer's disease.

  2004cited by this paper
• Dissecting the pathological effects of human Aβ40 and Aβ42 in Drosophila: A potential model for Alzheimer's disease

  2004cited by this paper
• Stages in the development of Parkinson’s disease-related pathology

  2004cited by this paper
• Regulation of Aging and Age-Related Disease by DAF-16 and Heat-Shock Factor

  2003cited by this paper
• Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy

  2003cited by this paper
• Mechanism of Toxicity in Rotenone Models of Parkinson's Disease

  2003cited by this paper
• Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.

  2003cited by this paper
• Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders

  2003cited by this paper
• Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction.

  2003cited by this paper
• Normal cognitive behavior in two distinct congenic lines of transgenic mice hyperexpressing mutant APP SWE.

  2003cited by this paper
• Huntingtin in health and disease.

  2003cited by this paper
• Intranigral infusion of interleukin‐1β activates astrocytes and protects from subsequent 6‐hydroxydopamine neurotoxicity

  2003cited by this paper
• Early Motor Dysfunction and Striosomal Distribution of Huntingtin Microaggregates in Huntington's Disease Knock-In Mice

  2002cited by this paper
• Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity

  2002cited by this paper
• Alzheimer's Disease Is a Synaptic Failure

  2002cited by this paper
• Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila.

  2002cited by this paper
• The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans

  2002cited by this paper
• Mouse models of Huntington's disease.

  2002cited by this paper
• Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice.

  2002cited by this paper
• Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP

  2001cited by this paper
• Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils

  2001cited by this paper
• Neurological abnormalities in a knock-in mouse model of Huntington's disease.

  2001cited by this paper
• Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death

  2001cited by this paper
• Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation.

  2001cited by this paper
• Tauopathy in Drosophila: Neurodegeneration Without Neurofibrillary Tangles

  2001cited by this paper
• Apoptosis in the nervous system

  2000cited by this paper
• The CA1 Region of the Human Hippocampus Is a Hot Spot in Alzheimer's Disease

  2000cited by this paper
• Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila.

  2000cited by this paper
• Apoptosis in neurodegenerative disorders

  2000cited by this paper
• Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice.

  2000cited by this paper
• Neuroprotective Effects of Creatine in a Transgenic Mouse Model of Huntington's Disease

  2000cited by this paper
• Impaired Proteasome Function in Alzheimer's Disease

  2000cited by this paper
• Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans.

  2000cited by this paper
• Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron.

  1999cited by this paper
• A putative Drosophila homolog of the Huntington's disease gene.

  1999cited by this paper
• Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease

  1999cited by this paper
• Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency.

  1999cited by this paper
• Characterization of Progressive Motor Deficits in Mice Transgenic for the Human Huntington’s Disease Mutation

  1999cited by this paper

• Characterization of the Proteomic Response in SIM-A9 Murine Microglia Following Canonical NLRP3 Inflammasome Activation

  2026cites this paper
• Experimental Models and Translational Strategies in Neuroprotective Drug Development with Emphasis on Alzheimer’s Disease

  2026cites this paper
• Brain targeted drug delivery using liposomes and polymeric nanocarriers: Pharmaceutical and preclinical perspectives in Alzheimer's and Parkinson's disease

  2026cites this paper
• AI and organoid platforms for brain-targeted theranostics

  2026cites this paper
• Telomere-driven senescence accelerates tau pathology, neuroinflammation and neurodegeneration in a tauopathy mouse model

  2025cites this paper
• Exploring the Role of Neuromodulation in Neurodegenerative Disorders: Insights from Alzheimer's Disease and Parkinson's Disease

  2025cites this paper
• Neurodegeneration emerges at a cellular tipping point between aggregate accumulation and removal

  2025cites this paper
• Electromagnetic Field Stimulation Effects on Intrinsically Disordered Proteins and Their Role in Aging and Neurodegeneration

  2025cites this paper
• Lack of ADAP1/Centaurin-α1 Ameliorates Cognitive Impairment and Neuropathological Hallmarks in a Mouse Model of Alzheimer's Disease

  2025cites this paper
• Multi-coil TMS for preclinical applications in ultra-high-field MRI

  2025cites this paper
• The genetic architecture of Parkinson’s disease on the Island of Crete

  2025cites this paper
• Divergent and convergent TMEM106B pathology in murine models of neurodegeneration and human disease

  2025cites this paper
• The Beneficial Effects of Berberine on Brain Functions in Age‐Related Neurological Disorders: From Molecular Signaling to Treatment

  2025cites this paper
• Pyruvate kinase deficiency links metabolic perturbations to neurodegeneration and axonal protection

  2025cites this paper
• Towards a Conceptual Framework to Better Understand the Advantages and Limitations of Model Organisms

  2025cites this paper
• Neurostimulation devices to treat Alzheimer’s disease

  2025influential citation
• Lipid-Based Nanomedicine for Alzheimer's Disease: A Comprehensive Review of Recent Advances.

  2024cites this paper
• Pharmacological targeting of dopamine D1 or D2 receptors evokes a rapid‐onset parkinsonian motor phenotype in mice

  2024cites this paper
• Renovating the Barnes maze for mouse models of Dementia with STARR FIELD: A 4-day protocol that probes learning rate, retention and cognitive flexibility

  2024cites this paper
• Impact of fixation duration on messenger RNA detectability in human formalin-fixed paraffin-embedded brain tissue

  2024cites this paper
• Expansion microscopy reveals neural circuit organization in genetic animal models

  2024cites this paper
• Comparison of Malondialdehyde, Acetylcholinesterase, and Apoptosis-Related Markers in the Cortex and Hippocampus of Cognitively Dysfunctional Mice Induced by Scopolamine

  2024cites this paper
• Brazilian kefir fraction mitigates the Alzheimer-like phenotype in Drosophila melanogaster with β-amyloid overexpression model

  2024cites this paper
• Exploring the Behavioral Traits of Male Mutant Crup Mice as an Experimental Neurodegenerative Disease Model

  2024cites this paper
• Effects of housing density on anxiety-like behavior of zebrafish in the plus maze with ramp.

  2024cites this paper
• Brainwaves Monitoring via Human Midbrain Organoids Microphysiological Analysis Platform: MAP

  2024cites this paper
• A Human Brain-Chip for modelling brain pathologies and screening of BBB crossing therapeutic strategies

  2024cites this paper
• Targeting inflammasome complexes as a novel therapeutic strategy for mood disorders

  2024cites this paper
• Integrative medicinal approaches towards Alzheimer's disease model animals–A new hope

  2024cites this paper
• Rodent Models of Alzheimer’s Disease: Past Misconceptions and Future Prospects

  2024influential citation
• Emergence of the brain-border immune niches and their contribution to the development of neurodegenerative diseases

  2024cites this paper
• Differential distribution of PINK1 and Parkin in the primate brain implies distinct roles

  2024cites this paper
• Loss of GDE2 leads to complex behavioral changes including memory impairment

  2024cites this paper
• The Interplay of Mitochondrial Bioenergetics and Dopamine Agonists as an Effective Disease-Modifying Therapy for Parkinson’s Disease

  2024cites this paper
• Long-term mouse spinal cord organotypic slice culture as a platform for validating cell transplantation in spinal cord injury

  2024cites this paper
• Comparative analysis of primate and pig cells reveals primate-specific PINK1 expression and phosphorylation

  2024cites this paper
• Metal mixture-induced non-transgenic animal model of Alzheimer’s disease: Pros and cons

  2023cites this paper
• Long-term organotypic brain slices cultured. on collagen-based microcontact prints: a perspective for a brain-on-a-chip.

  2023cites this paper
• Senolytic and senomorphic secondary metabolites as therapeutic agents in Drosophila melanogaster models of Parkinson’s disease

  2023cites this paper
• Animal Models of Human Disease

  2023cites this paper
• Pain and aging: A unique challenge in neuroinflammation and behavior

  2023cites this paper
• A viral vector model for circuit-specific synucleinopathy

  2023cites this paper
• A multi-channel TMS system enabling accurate stimulus orientation control during concurrent ultra-high-field MRI for preclinical applications

  2023cites this paper
• Beyond animal models: revolutionizing neurodegenerative disease modeling using 3D in vitro organoids, microfluidic chips, and bioprinting

  2023cites this paper
• Turquoise killifish: a natural model of age-dependent brain degeneration.

  2023cites this paper
• Three‐dimensional bioprinting of stem cell‐derived central nervous system cells enables astrocyte growth, vasculogenesis, and enhances neural differentiation/function

  2023cites this paper
• Endogenous recapitulation of Alzheimer’s disease neuropathology through human 3D direct neuronal reprogramming

  2023cites this paper
• Inflammation-Mediated Responses in the Development of Neurodegenerative Diseases.

  2023cites this paper
• Genetic modifiers of synucleinopathies—lessons from experimental models

  2023cites this paper
• The Drosophila blood-brain barrier emerges as a model for understanding human brain diseases.

  2023cites this paper
• Lifespan Changes in Brain Structure and Cognitive Performance Associated with Normal Aging in Mice

  2023cites this paper
• Functionalized carbon nanotubes—A boon in treating brain diseases

  2023cites this paper
• Is environmental enrichment beneficial for laboratory animals? A systematic review of studies in zebrafish

  2023cites this paper
• Applications of microphysiological systems to disease models in the biopharmaceutical industry: Opportunities and challenges.

  2023cites this paper
• In Vitro 3D Modeling of Neurodegenerative Diseases

  2023cites this paper
• Mammalian Models in Alzheimer’s Research: An Update

  2023cites this paper
• 25-hydroxycholesterol mediates brain cytokine production and neutrophil infiltration in a mouse model of lipopolysaccharide-induced neuroinflammation

  2023cites this paper
• A deep-learning-based screening platform in aging-relevant human motor neurons to identify therapeutic compounds for amyotrophic lateral sclerosis

  2023cites this paper
• Development and Optimization of A High-Throughput 3D Rat Purkinje Neuron Culture to Study Paraneoplastic Cerebellar Degeneration

  2022cites this paper
• Dysregulated Brain Protein Phosphorylation Linked to Increased Human Tau Expression in the hTau Transgenic Mouse Model

  2022cites this paper
• Mice in translational neuroscience: What R we doing?

  2022cites this paper
• Microscopic-scale recording of brain neuronal electrical activity using a diamond quantum sensor

  2022cites this paper
• Modeling of Neurodegenerative Diseases: ‘Step by Step’ and ‘Network’ Organization of the Complexes of Model Systems

  2022influential citation
• Protective effect of Amazonian Himatanthus sucuuba extracts in Drosophila melanogaster exposed to Paraquat

  2022cites this paper
• Organotypic cultures as aging associated disease models

  2022cites this paper
• Brain Organoids to Evaluate Cellular Therapies

  2022cites this paper
• 3D Bioprinting of Stem Cell-Derived Central Nervous System Cells Enables Astrocyte Growth, Vasculogenesis and Enhances Neural Differentiation/Function

  2022cites this paper
• Caenorhabditis elegans as a model system to evaluate neuroprotective potential of nano formulations

  2022cites this paper
• Novel inductively-coupled ear-bars (ICEs) for fMRI signal enhancement in rat entorhinal cortex

  2022cites this paper
• A Review on Neurodegenerative Diseases with their Suitable Animal Models

  2022influential citation
• Advances in human brain proteomics analysis of neurodegenerative diseases

  2022cites this paper
• Glycolysis: The Next Big Breakthrough in Parkinson’s Disease

  2022cites this paper
• Antimicrobial and antioxidant activity of Panax ginseng and Hedysarum neglectum root crop extracts.

  2022cites this paper
• Nuclear GAPDH in cortical microglia mediates stress-induced cognitive inflexibility

  2022cites this paper
• Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

  2022cites this paper
• Inflammasome activation and assembly in Huntington's disease.

  2022cites this paper
• Intrathecal amyloid‐beta oligomer administration increases tau phosphorylation in the medial temporal lobe in the African green monkey: A nonhuman primate model of Alzheimer's disease

  2022cites this paper
• Current approaches to characterize micro- and macroscale circuit mechanisms of Parkinson’s disease in rodent models

  2022cites this paper
• Animal Models Used for Studying the Benefits of Probiotics in Neurodegeneration

  2022cites this paper
• iPSCs in Neurodegenerative Disorders: A Unique Platform for Clinical Research and Personalized Medicine

  2022cites this paper
• Convergent pathways of the gut microbiota–brain axis and neurodegenerative disorders

  2022cites this paper
• Nonrespiratory sites of influenza‐associated disease: mechanisms and experimental systems for continued study

  2022cites this paper
• Quantifying unusual neurological movement phenotypes in collective movement phenotypes

  2021cites this paper
• Programmed Morphogenesis: Methods and Protocols

  2021cites this paper
• Molecular Network for Management of Neurodegenerative Diseases and their Translational Importance using Animal Biotechnology as a Tool in Preclinical Studies

  2021cites this paper
• Modeling Brain Pathology of Niemann‐Pick Disease Type C Using Patient‐Derived Neurons

  2021cites this paper
• Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders

  2021cites this paper
• Photodynamic studies reveal rapid formation and appreciable turnover of tau inclusions

  2021cites this paper
• Ghrelin as a treatment for amyotrophic lateral sclerosis

  2021cites this paper
• Non-cell autonomous astrocyte-mediated neuronal toxicity in prion diseases

  2021cites this paper
• Targeting for Success: Demonstrating Proof-of-Concept with Mechanistic Early Phase Clinical Pharmacology Studies for Disease-Modification in Neurodegenerative Disorders

  2021cites this paper
• The Emerging Role of Neuronal Organoid Models in Drug Discovery: Potential Applications and Hurdles to Implementation

  2021cites this paper
• Use of CRISPR/Cas9-mediated disruption of CNS cell type genes to profile transduction of AAV by neonatal intracerebroventricular delivery in mice

  2021cites this paper
• Improving mitochondria and ER stability helps eliminate upper motor neuron degeneration that occurs due to mSOD1 toxicity and TDP‐43 pathology

  2021cites this paper
• Computational Analysis Indicates That PARP1 Acts as a Histone Deacetylases Interactor Sharing Common Lysine Residues for Acetylation, Ubiquitination, and SUMOylation in Alzheimer’s and Parkinson’s Disease

  2021cites this paper
• Animal and Cellular Models of Alzheimer’s Disease: Progress, Promise, and Future Approaches

  2021cites this paper
• A New Approach to Model Sporadic Alzheimer’s Disease by Intracerebroventricular Streptozotocin Injection in APP/PS1 Mice

  2021cites this paper
• The Potential of Induced Pluripotent Stem Cells to Test Gene Therapy Approaches for Neuromuscular and Motor Neuron Disorders

  2021cites this paper
• Quantification of Dendritic Spines Remodeling under Physiological Stimuli and in Pathological Conditions

  2021cites this paper
• Engineering Biocompatible Hydrogel Fibers With Tunable Mechanical Properties For Neural Tissue Engineering

  2021cites this paper